EUVIMEDEUVIMED entdecken
Open Access

Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias

Meenakshi Venkatasubramanian iD, Leya Schwartz iD, Nandini Ramachandra iD, Joshua Bennett, Krithika R Subramanian iD, Xiaoting Chen, Shanisha Gordon-Mitchell, Ariel Fromowitz, Kith Pradhan, David Shechter iD, Srabani Sahu, Diane Heiser iD und 12 weitere

Science Translational Medicine · 07.05.2025 · 17 (797)

DOI: 10.1126/scitranslmed.adr1471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 07.05.2025. Verfasst von Meenakshi Venkatasubramanian und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. Hauptthemen laut MEDLINE: RNA Splicing, Leukemia, Precision Medicine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NINDS NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of splicing dysregulation in cancer is underscored by splicing factor mutations; however, its impact in the absence of such rare mutations remains poorly understood. Prompted by the finding that splicing uniquely resolved genetic subtypes of cancer, we developed an unsupervised computational workflow called OncoSplice to comprehensively define tumor molecular landscapes. In adult and pediatric acute myeloid leukemia (AML), OncoSplice identified the spectrum of driver genetics from splicing profiles alone, defined more than a dozen previously unreported molecular subtypes recurrent across AML cohorts, and discovered a dominant splicing subtype that partially phenocopies U2AF1 -mutant splicing. Although pediatric leukemias lack splicing factor mutations, this U2AF1 -like subtype similarly spanned pediatric and adult AML genetics and consistently predicted poor prognosis. Using long-read single-cell RNA sequencing, we confirmed that discovered U2AF1 -like splicing was shared across cell states, co-opted a healthy circadian gene program, was stable through relapse, and induced a leukemic stem cell program. Pharmacological inhibition of an implicated U2AF1 -like splicing regulator, PRMT5, rescued leukemia missplicing and inhibited leukemic cell growth. Finally, genetic deletion of IRAK4 , a common target of U2AF1 -like and PRMT5 treatment, blocked leukemia development in xenograft models and induced differentiation. This work suggests that broad splicing dysregulation, in the absence of select mutations, is a therapeutic target in heterogeneous leukemias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA SplicingLeukemiaPrecision MedicineHumansSplicing Factor U2AFAnimalsMutationLeukemia, Myeloid, AcuteCell Line, TumorMiceNeoplastic Stem Cells

Substanzen

Splicing Factor U2AF

Autor:innen und Institutionen

  • Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Department of Electrical Engineering and Computer Science, University of Cincinnati, Cincinnati, OH 452293, USA.
  • Department of Oncology, Blood Cancer Institute, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY 10461, USA.
  • Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

ORCID-Profile: Meenakshi Venkatasubramanian, Leya Schwartz, Nandini Ramachandra, Krithika R Subramanian, David Shechter, Diane Heiser, Peggy Scherle, Kashish Chetal, Kasiani C Myers, Matthew T Weirauch, Daniel T Starczynowski, Amit Verma, Nathan Salomonis

Förderung

  • NHLBI NIH HHS
  • NINDS NIH HHS
  • NIAMS NIH HHS
  • NCI NIH HHS
  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Venkatasubramanian, M., Schwartz, L., Ramachandra, N., Bennett, J., Subramanian, K. R., Chen, X., Gordon-Mitchell, S., Fromowitz, A., Pradhan, K., Shechter, D., Sahu, S., Heiser, D., Scherle, P., Chetal, K., Kulkarni, A., Lee, D., Zhou, J., Myers, K. C., Tseng, E., …, & Salomonis, N. (2025). Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias. Science Translational Medicine, 17(797). https://doi.org/10.1126/scitranslmed.adr1471

Vancouver

Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, et al. Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias. Science Translational Medicine. 2025;17(797). doi:10.1126/scitranslmed.adr1471

BibTeX
@article{Venkatasubramanian2025,
  author = {Venkatasubramanian, Meenakshi and Schwartz, Leya and Ramachandra, Nandini and Bennett, Joshua and Subramanian, Krithika R and Chen, Xiaoting and Gordon-Mitchell, Shanisha and Fromowitz, Ariel and Pradhan, Kith and Shechter, David and Sahu, Srabani and Heiser, Diane and Scherle, Peggy and Chetal, Kashish and Kulkarni, Aishwarya and Lee, Davy and Zhou, Jeff and Myers, Kasiani C and Tseng, Elizabeth and Weirauch, Matthew T and Grimes, H Leighton and Starczynowski, Daniel T and Verma, Amit and Salomonis, Nathan},
  title = {Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {797},
  doi = {10.1126/scitranslmed.adr1471}
}
Kostenlos starten →